3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Ovarian Neoplasms
9
Fallopian Tube Neoplasms
8
Breast Neoplasms
6
Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Recurrence
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Small Cell Lung Carcinoma
2
Metastatic Castration Resistant Prostate Cancer
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Prostate Cancer Metastatic
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Lung Neoplasms
1
Genital Neoplasms, Male
1
Genital Neoplasms, Female
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Advanced Gastric Cancer
1
Adenocarcinoma, Clear Cell
1
Adenocarcinoma of Lung
1
Interventions
enzalutamide
9
Abiraterone Acetate
5
rucaparib
2
Prednisone
2
Docetaxel
2
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Blood Specimen Collection
1
Biopsy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Castration Resistant Prostate Cancer
×
rucaparib
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA
NCT04179396
2023-06-29
RAMP
pharmaand GmbH
Phase 1
Completed
8 enrolled
8 charts